A New Approach to Cord Blood Banking
Americord® is committed to pioneering the development of new cord blood, cord tissue, and placenta tissue banking technologies. Under the leadership of Executive Medical Director, Dr. Robert Dracker, Americord® developed Cord Blood 2.0™. This revolutionary extraction process harvests up to twice as many stem cells compared to a traditional cord blood collection.
As a rich source of Hematopoietic Stem Cells (HSCs), cord blood has a number of advantages, including decreased risk of severity of Graft-Versus-Host-Disease (GCHD) and a lower risk of transmissible infectious disease. However, the usefulness of cord blood in stem cell therapy has been limited by the relatively small amount of blood that can be collected using standard procedures. With Cord Blood 2.0™, Americord® is making cord blood banking a lifelong investment with the possibility of treating patients well into adulthood.
GET ACCESS TO OUR INFO GUIDE
From Our Medical Director
We’d like to extend our sincere gratitude to the thousands of obstetricians, nurses, midwives, and childbirth educators who support placenta and umbilical cord blood banking. There is no doubt that these efforts save lives.
Americord is committed to playing an important role in the growth of this new industry. This section of the website was created for you. To facilitate valuable communications within our industry we will post scientific information about our own processes and research as well as information that is being published about research being done throughout our industry, all of which is meant to offer additional resources for you.
I am eager to hear from you. If you have questions, comments or want to learn more about working with Americord, please click here.
Dr. Robert Dracker, MD, MHA, MBA
Executive Medical Director